| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | 0 | 0 | 0 | 0 |
| Research and development | 89,953,000 | 60,153,000 | 41,391,000 | 22,785,000 |
| General and administrative | 8,608,000 | 14,421,000 | 14,078,000 | 13,771,000 |
| Total operating expenses | 98,561,000 | 74,574,000 | 55,469,000 | 36,556,000 |
| Loss from operations | -98,561,000 | -74,574,000 | -55,469,000 | -36,556,000 |
| Amortization of financing costs | 8,000 | 24,000 | 24,000 | 24,000 |
| Interest income, net | 7,772,000 | 9,033,000 | 9,864,000 | 11,531,000 |
| Realized gain on investments, net | 10,000 | 4,000 | - | 109,000 |
| Total other income, net | 7,774,000 | 9,013,000 | 9,840,000 | 11,616,000 |
| Net loss | -90,787,000 | -65,561,000 | -45,629,000 | -24,940,000 |
| Unrealized gain on securities | 540,000 | 26,000 | 563,000 | 3,902,000 |
| Foreign currency translation gain (loss) | 0 | 24,000 | 9,000 | 2,000 |
| Comprehensive loss | -90,247,000 | -65,511,000 | -45,057,000 | -21,036,000 |
| Earnings per share, basic | -0.81 | -0.58 | -0.41 | -0.22 |
| Earnings per share, diluted | -0.81 | -0.58 | -0.41 | -0.22 |
| Weighted average number of shares outstanding, basic | 112,320,000 | 112,134,000 | 112,069,000 | 110,911,000 |
| Weighted average number of shares outstanding, diluted | 112,320,000 | 112,134,000 | 112,069,000 | 110,911,000 |
Viking Therapeutics, Inc. (VKTX)
Viking Therapeutics, Inc. (VKTX)